When used in a real-world setting, Ofev (nintedanib) significantly prolonged the survival of idiopathic pulmonary fibrosis (IPF) patients,…
Articles by Lindsey Shapiro, PhD
Dosing is now complete in the Phase 2b GALACTIC-1 trial of GB0139 for treating idiopathic pulmonary fibrosis (IPF).
The dynamics of the extracellular matrix (ECM) that surrounds cells and gives structure to tissues may play an important role…
Vyne Therapeutics‘ experimental inhaled therapy VYN201 led to significant reductions in lung fibrosis and improvements in lung function in…
The use of aspirin, a common over-the-counter medicine, showed benefits in mouse and cell models of pulmonary fibrosis (PF)…
Certain populations of immune monocytes and macrophages may be important targets of mesenchymal stem cell (MSC) therapy in idiopathic…
The highest tested dose of bexotegrast, an anti-fibrotic treatment candidate from Pliant Therapeutics, was found to best — and…
TXR-1002, Aria Pharmaceuticals’ investigational candidate for idiopathic pulmonary fibrosis (IPF), effectively prevented the buildup of scar tissue, or…
A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic…
The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability,…